Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.54 |
| ▸ | FLT3 | P36888 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3017898 | 0.94 | CDK2 (0.51) | BTKFLT3CDK2CCNE1SYK | |
| SCHEMBL3618938 | 0.85 | FLT3 (0.62) | BTKFLT3CDK2CCNE1SYK | |
| SCHEMBL3023189 | 0.84 | CDK2 (0.52) | BTKFLT3CDK2CCNE1SYK | |
| SCHEMBL3012108 | 0.82 | FLT3 (0.46) | BTKFLT3CDK2CCNE1SYK | |
| SCHEMBL3023084 | 0.81 | CDK2 (0.50) | FLT3CDK2CCNE1SYKMAPKAPK2 | |
| SCHEMBL3018859 | 0.81 | CDK2 (0.50) | FLT3CDK2CCNE1SYKMAPKAPK2 | |
| SCHEMBL3018072 | 0.80 | BTK (0.53) | BTKFLT3CHEK1PRKCI | |
| SCHEMBL4708842 | 0.79 | CCNE1 (0.70) | FLT3CDK2CCNE1 | |
| SCHEMBL3018299 | 0.79 | FLT3 (0.49) | FLT3CDK2CCNE1CHEK1MAPKAPK2 | |
| SCHEMBL3010145 | 0.78 | CCNE1 (0.69) | FLT3CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| WO-2008116064-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | BTK 1/4885FLT3 11/4885CDK2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.